S9630, Medroxyprogesterone in Treating Women With Breast Cancer

Completed · Phase 3

Conditions studied: Breast Cancer, Endometrial Cancer

In brief

RATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen. PURPOSE: Randomized phase III trial to study the effectiveness of medroxyprogesterone in preventing endometrial disorder in postmenopausal women who have ductal carcinoma in situ, lobular carcinoma in situ, Paget's disease of the nipple, stage I breast cancer, or stage II breast cancer and who are taking tamoxifen.

Key facts

Study ID
NCT00002920
Run by
SWOG Cancer Research Network
People needed
313
Starts
1997-03-01
Expected to finish
2009-12-01
Last updated by the study team
2012-10-31

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.